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Chemosensitivea b s t r a c t
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma
that is characterized by unique clinical presentation, histological appearance, and indolent disease course.
The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its
management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with
high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median
follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%)
and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous trans-
plantation should be considered as an option for patients with relapsed NLPHL.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Of the 8000 cases of Hodgkin lymphoma (HL) diagnosed in
the United States each year, 5% to 10% are further classiﬁed as
nodular lymphocyte-predominant HL (NLPHL). Descriptions
of NLPHL ﬁrst appeared in the literature in 1936, with the
extent of lymphocyte proliferation in the involved lymph
nodes suggestive of an improvement in overall survival [1]. In
Table 1
Patient Characteristics (N ¼ 26)
Characteristic Value










B symptoms 7 (26.9)
No. prior chemotherapy regimens, median (range) 3 (1-4)
Prior radiation therapy 12 (46.2)
Prior rituximab 14 (53.8)
Disease status at transplantation
Complete remission 9 (34.6)
Partial remission 13 (50)
Stable disease 1 (3.8)
Progressive disease 3 (11.5)
Median (range) duration from time of diagnosis to






Bone marrow 3 (11.5)
Peripheral blood 23 (88.4)









Large-cell lymphoma 8 (30.7)
BEAM-R indicates carmustine, etoposide, cytarabine, melphalan, and
rituximab; BEAM, carmustine, etoposide, cytarabine, and melphalan; CBV,
cyclophosphamide, carmustine, and etoposide; NLPHL, nodular
lymphocyte-predominant Hodgkin lymphoma.
Data are presented as n (%) unless otherwise indicated.
* Includes busulfan/melphalen, mitoxantrone/etoposide/thiotepa, BEAM-
R/Zevalin, BEAC (carmustine, etoposide, cytarabine, melphalan, and
cyclophosphamide).
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lymphoid neoplasms recognized this rare clinico-pathological
entity of NLPHL not only on the basis of lymphocyte
predominance but also on the presence of larger atypical,
CD20 positive cells known as lymphocyte-predominant cells,
previously called L & H cells or Reed-Sternberg cell variants [2].
The publication of nearly 2 dozen retrospective series has
elucidated clinical features of >1500 cases of HL. Clinical
features distinguishing NLPHL from classical HL include
a greater male predominance (3:1), older median age at
presentation (30 to 40 years), and lower incidence of medi-
astinal involvement (<15%). Additionally, certain risk factors
classically associated with HL (including presence of B symp-
toms, elevated erythrocyte sedimentation rate, bulky disease,
andmultiple sites of nodal involvement) are less prevalent [1].
The majority of patients present with limited-stage
disease with response rates to primary therapy exceeding
90%. Ten percent to 35% of patients relapse after achieving an
initial complete remission, however, with a median time to
ﬁrst relapse of 3 to 6 years [1]. Data have shown that those
with early unfavorable and advanced stages of NLPHL have
outcomes similar to those with classical HL. Although not
evidence based, the treatment of advanced-stage NLPHL
typically includes rituximab in combination with either
Adriamycin, cyclophosphamide, vincristine, decarbazine
(ABVD) or cyclophosphamide, doxorubicin, vincristine,
prednisone (CHOP), given that the malignant cells of NLPHL
express the CD20 antigen [3-5]. Such therapy is associated
with long-term remissions in many, but eventually some
patients will relapse. At present, there is no uniform data on
the outcome of second-line therapy, as there is no consensus
onwhich type of treatment should be used. Furthermore, the
role of autologous stem cell transplantation (ASCT) in this
setting remains poorly described. In this study, we report our
experience with ASCT for patients with relapsed NLPHL.
METHODS
The selected study population included 26 patients with relapsedNLPHL
who underwent high-dose chemotherapy and autologous transplantation at
the University of Texas MD Anderson Cancer Center between January 1990
and December 2008. Data were collected from an institutional database of
blood and marrow transplantation recipients and from review of patient
records. The institutional review board approved this retrospective review.
All pathology specimens were reviewed by pathologists at MD Anderson to
ensure concordance with the WHO 2008 criteria. According to the WHO
2008 guidelines, NLPHL is characterized by the presence of a nodular
proliferation of scattered neoplastic cells, known as lymphocyte-predomi-
nant cells, occurring in a background of non-neoplastic lymphocytes and
histiocytes inﬁltrating a network of follicular dendritic cells. Of the 26
patients, 8 (31%) were noted to have transformation of their disease to large-
cell lymphoma (LCL) at the time of relapse [6].
Responsiveness to therapy was assessed using the International Work-
shop Criteria published in 1999 [7]. Patients were recognized either as
having a complete response, partial response, stable disease, or progressive
disease. They were also classiﬁed on the basis of chemosensitivity, with
those with either partial response or complete response before trans-
plantation deﬁned as being “chemosensitive.”
Probabilities of outcomes were calculated utilizing the Kaplan-Meier
method. Both overall survival (OS) and event-free survival (EFS) were
measured inmonths, starting from the date of transplantation. EFS indicated
the time to disease relapse, progression, or death independent of cause.
RESULTS AND DISCUSSION
Patient characteristics are summarized in Table 1. At the
time of transplantation, 9 patients (35%) were in complete
response, 13 patients (50%) were in partial response, and 4
patients (15%) had stable disease or progressive disease. At
the time of transplantation, 18 patients (70%) had histology
consistent with NLPHL, and 8 (30%) had evidence oftransformation to LCL. Seven of 18 patients (39%) who were
histologically proven to have NLPHL at the time of relapse
had advanced disease at the time of initial diagnosis, as
compared with 6 of 8 (75%) with ultimate transformation to
LCL. At the time of relapse, the vast majority of patients with
both NLPHL and transformed LCL had advanced-stage
disease: 17 of 18 patients (94%) with NLPHL and 8 of 8 (100%)
with transformed disease. Although lactate dehydrogenase
values were not available in all patients at relapse, it was
elevated in 3 of 10 (30%) patients with NLPHL and 2 of 7 (29%)
with transformed LCL. Seven patients (27%) had the presence
of B symptoms at the time of transplantation. Pre-
transplantation lactate dehydrogenase was elevated in 10 of
22 patients (38%). Median age at time of transplantation was
35 years (range, 13-51).
Median number of prior chemotherapy regimens was
3 (range, 1-4), and 12 patients (46.2%) were treated with
involved ﬁeld radiation therapy before transplantation.
Fourteen patients (53.8%) received rituximab; 4 in the ﬁrst-
line setting, 11 in the salvage setting, and 9 as a part of
their conditioning regimen before transplantation.
The median duration of time from the initial diagnosis to
autologous transplantation was 35.2 months (range, 9.2-
Figure 1. Event-free and overall survival at 5 years. Median follow-up of 50
months (range, 2-138 months).
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frequency, from highest to lowest, were R-BEAM (rituximab,
carmustine, etoposide, cytarabine, and melphalan), CBV
(cyclophosphamide, carmustine, and etoposide), and BEAM
(carmustine, etoposide, cytarabine, and melphalan). The
remaining 5 patients were treated with various other
conditioning regimens. Peripheral blood stem cells were
used as a stem cell source in 23 (86%) patients. All patients
engrafted after transplantation.
Following transplantation, 22 patients were in complete
remission. No treatment-related mortality or treatment-
related myelodysplastic syndrome and/or acute myeloge-
nous leukemia occurred in any of the patients included in the
study. Ultimately, 7 patients relapsed. Among them, only one
relapsed with diffuse large B cell lymphoma, whereas the
remainder had return of their NLPHL. Three out of 4 patients
(75%) with chemoresistent disease relapsed, as compared
with 4 out of 22 (18%) patients with chemosensitive disease.
As summarized in Table 2 and depicted in Figure 1, the
5-year EFS and OS at amedian follow-up period of 50months
(range, 2-138 months) were 69% (SE, 10%) and 76% (SE, 10%),
respectively. In patients with chemosensitive disease, the 5-
year EFS and OS were 79% (SE 10%) and 82% (SE 10%),
respectively. Of the 26 patients in the series, 18 patients had
relapse of their original histology of NLPHL at the time of
transplantation, and 8 patients transformed to LCL. The
5-year EFS and OS for those with NLPHL were 61% (SE 12%)
and 73% (SE 12%), respectively. For thosewith transformation
to LCL at the time of transplantation, EFS and OS were 87%
(SE 12%) and 87% (SE 12%) respectively. At the conclusion of
the follow-up period, 6 deaths occurred on account of
progressive disease.
Although not supported by clinical trial data, patients
with relapsed NLPHL are often treated with autologous
transplantation. Historically, 2 randomized trials have shown
that patients with relapsed HL derive a signiﬁcant beneﬁt
from autologous stem cell transplantation over conventional
therapy in regard to freedom from treatment failure, even
among those with favorable disease characteristics [5,8,9].
The lack of survival beneﬁt has been attributed to the ulti-
mate transplantation of those with relapsed disease initially
assigned to the nontransplanted arm [10]. Literature specif-
ically looking at autologous transplantation in the setting of
NLPHL is limited and includes very few patients. Jackson
et al. [11] reported a median failure-free survival of 39.2Table 2
Patient Outcomes (N ¼ 26)
Outcome Result
Engraftment
Absolute neutrophil count>500/mm3 10 (8-33) d
Platelets >20,000/mm3 10 (7-35) d
Median follow-up, mo (range) 50 (2-138)
Cause of death
Disease progression, n 6
Nonrelapse mortality, n 0
Event-free survival at 5 yr 69% (SE 10%)
Overall survival at 5 yr 76% (SE 10%)
Chemosensitive patients (n ¼ 22)
Event-free survival at 5 yr 79% (SE 10%)
Overall survival at 5 yr 82% (SE 10%)
NLPHL (n ¼ 18)
Event-free survival at 5 yr 61% (SE 12%)
Overall survival at 5 yr 73% (SE 12%)
Large-cell lymphoma (n ¼ 8)
Event-free survival at 5 yr 87% (SE 12%)
Overall survival at 5 yr 87% (SE 12%)
NLPHL indicates nodular lymphocyte-predominant Hodgkin lymphoma.months (range, 28.6-138.5 months) for NLPHL patients
receiving autologous transplantation after achieving PR with
standard chemotherapy. Five of 8 patients in their series
experienced relapse after transplantation and went on to
receive further chemotherapy. Basioli et al. [12] reported 60%
OS in 19 patients with NLPHL transformed to LCL. They
showed that 9 of 164 patients who received autologous
transplantation for NLPHL and transformed to LCL had
OS comparable to the 10 transformed patients who received
salvage systemic therapies. Bierman et al. [13] reported on 19
patients treated with ASCT for relapsed or refractory NLPHL.
Treatment outcomes were compared with 299 patients
treated with ASCT for relapsed/refractory nodular sclerosing
HL. Both progression-free survival and OS were similar with
a 5-year progression-free survival after ASCT for patients
with NLPHL of 50% compared to 39% of patients with nodular
sclerosis HD (P ¼ .30) and a 5-year OS of 56% and 53%,
respectively (P ¼ .36).
These results, along with our data, suggest that autologous
transplantation is a potentially curative option for patients
with relapsed NLPHL, particularly in the setting of chemo-
sensitive disease. The low incidence rate of NLPHL precludes
the development of prospectively designed randomized clin-
ical trials evaluating the optimal therapeutic approach to this
subset of patients. Aside from the limitations inherent to
retrospective studies, the small number of patients available
for review precluded the development of univariate or multi-
variate analysis to uncover speciﬁc patient characteristics
predictive of outcome. The role of rituximab as a part of the
conditioning regimen in autologous transplantation also
remains unanswered. Following suit with several other
diseases, those with chemoresistant disease appear to be
ahigher risk for relapse following transplantation. In summary,
autologous transplantation is a reasonable therapeutic alter-
native for patients with relapsed or transformed NLPHL.ACKNOWLEDGMENTS
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Antibiotic prophylaxisa b s t r a c t
Although autologous and allogeneic hematopoietic stem cell transplantation (HSCT) are fundamentally
different procedures, a tailored approach to bacterial bloodstream infection (BSI) according to the type of
HSCT has not yet been suggested. We evaluated the characteristics of BSI after HSCT, with a focus on
comparison of BSIs between recipients of autologous HSCT (auto-HSCT) and allogeneic HSCT (allo-HSCT).
Among 134 patients (59 received allo-HSCT and 75 received auto-HSCT) who underwent HSCT, BSIs were
reported earlier in patients who underwent auto-HSCT, compared with those who underwent allo-HSCT
(mean 12.1  3.4 days versus 32.8  27.1 days, P ¼ .006). Among patients receiving allo-HSCT, post-
neutrophil-engraftment bacterial BSI showed an association with grade 2 acute graft-versus-host disease
(GVHD). In patients who underwent auto-HSCT, results of multivariate analysis showed that not receiving
prophylactic antibiotics (P ¼ .004) and having elevated serum C-reactive protein (P ¼ .034) were risk factors of
BSI. Elevated CRP (P ¼ .01) and acute GVHD  grade 2 (P ¼ .002) were independent risk factors in patients
who underwent allo-HSCT. Those differences originated mainly from the impact of acute GVHD-related
postengraftment BSIs of patients who underwent allo-HSCT. To establish the best defense strategy against
BSI, the distinctive natures of bacterial BSI after HSCT between auto-HSCT and allo-HSCT should be
considered.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Bacterial bloodstream infection (BSI) is a common and
sometimes fatal event in patients who undergo hematopoi-
etic stem cell transplantation (HSCT). Although advances in
HSCT, such as the use of prophylactic antibiotics, reduced-
intensity conditioning (RIC), and improved supportive care,
have contributed to a substantial reduction of morbidity and
mortality, the incidence of bacterial BSI has been reported to
range from 20% to 43%, even after the year 2000 [1-4].
